Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$2.07 USD
-0.01 (-0.24%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $2.19 +0.13 (6.05%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CHRS 2.07 -0.01(-0.24%)
Will CHRS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHRS
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody
Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down
Other News for CHRS
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
AbbVie keeps Humira market share near 100% despite biosimilars: report
Commit To Purchase Coherus BioSciences At $2, Earn 32.2% Annualized Using Options
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting